United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 3 minute read Technology Industry News Can CommScope’s debt-free reboot unlock new growth for RUCKUS and ANS in 2026? After selling CCS to Amphenol for $10.5B, CommScope is going debt-free. Can RUCKUS and ANS drive its next growth chapter? byPallavi MadhirajuAugust 11, 2025